



350 - 4243 Glanford Ave. Victoria, BC Canada V8Z 4B9  
Tel: (250) 744-2811 Fax: (250) 744-2877 www.stressgen.com

**STRESSGEN SCIENTISTS AND KEY MIT COLLABORATORS  
PRESENT AT INTERNATIONAL SYMPOSIUM ON HEAT SHOCK  
PROTEINS IN BIOLOGY AND MEDICINE**

***Data Reinforces Utility of Heat Shock Protein Fusions as Platform  
for Development of Novel Immunotherapeutics***

FOR IMMEDIATE RELEASE

November 8th, 2000

**Woods Hole, Massachusetts** - Stressgen Biotechnologies Corp. (TSE: SSB) announces the presentation of preclinical data on the immune response to the HspE7 fusion protein at the International Symposium on Heat Shock Proteins in Biology and Medicine, a scientific conference sponsored by Harvard Medical School and the Dana Farber Cancer Institute held this week in Woods Hole, MA. This data will be published in the upcoming issue of the journal *Cell Stress and Chaperones*. Results published in this report are consistent with the clinical application of HspE7 as an immunotherapy for HPV-related diseases such as cervical and anal dysplasia and cancer. HspE7 is based on Stressgen's proprietary fusion protein platform technology.

"Stressgen's presence at this conference reflects our position at the forefront of heat shock protein based immunotherapeutics," said Dr. Marvin Siegel, Executive VP Research and Development at Stressgen. "Our data and the data of our collaborators represent the growing body of information that clearly establishes the utility of this technology as a platform to build our product pipeline."

Other presentations made by Stressgen collaborators, Richard A. Young, Ph.D., Professor of Biology, Massachusetts Institute of Technology (MIT) and a member of the Whitehead Institute for Biomedical Research and Herman Eisen, M.D., Professor of Immunology Emeritus, MIT, reinforce previous reports on Hsp fusion proteins mechanism of action, specifically leading to the activation of cytotoxic T cells and the production of cytokines associated with a cell mediated immune response.

Stressgen's lead product HspE7, which targets a variety of HPV-related diseases, is now in a Phase III trial for anal dysplasia. The Company also has active Phase II trials in cervical cancer and cervical dysplasia and plans to initiate a Phase II trial in genital warts. In addition, Stressgen has developed a variety of other Hsp fusion proteins for the treatment of other viral infections and related cancers, such as Hepatitis and HIV as well as asthma and allergy.

HspE7 is based on Stressgen's proprietary Hsp fusion technology. HspE7, a recombinant fusion product, is composed of heat shock protein 65 (Hsp65) from *Mycobacterium-bovis* BCG and the protein E7. As a member of the family of stress proteins, Hsp65 is known to elicit a powerful immune response. The E7 protein is derived from the HPV and is involved in the malignant transformation of epithelial cells. E7 is a tumor-specific antigen and represents a precise target for the immune system attack on abnormal cells.

-more-

Stressgen Biotechnologies is a biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. Through its Biochemical Division, Stressgen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.

-30-

Contact: Elisabeth Whiting, Director, Corporate Communications & Investor Relations  
Stressgen Biotechnologies, 350-4243 Glanford Ave. Victoria, BC V8Z 4B9  
Tel. 250-744-2811 Fax 250-744-3331 Email. [ewhiting@Stressgen.com](mailto:ewhiting@Stressgen.com)

*This foregoing press release may contain statements that are not based on historical fact, including, without limitation, statements containing the words "believes", "may", "will", "intends", "plans", "expects" and words of similar import. Such statements may constitute "forward-looking" statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. A number of factors could cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements implied by such statements. Such factors include, but are not limited to, those with respect to the timing of regulatory submissions and approvals, the ability of the Company to continue to develop its products (including HspE7), the Company's ability to maintain or expand its intellectual property position, the timing and success of planned or existing clinical trials and anticipated levels of revenues and expenses and others, all as described Company's Registration Statement on Form F-10 and other filings with the U.S. Securities and Exchange Commission.*

# # #